$16.10
5.09% yesterday
NYSE, May 20, 10:15 pm CET
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Mineralys Therapeutics Stock price

$16.10
+2.86 21.60% 1M
+3.50 27.78% 6M
+3.79 30.79% YTD
+3.29 25.68% 1Y
-2.34 12.69% 3Y
-2.34 12.69% 5Y
-2.34 12.69% 10Y
NYSE, Closing price Tue, May 20 2025
+0.78 5.09%
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Key metrics

Market capitalization $1.05b
Enterprise Value $706.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.06
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-201.49m
Free Cash Flow (TTM) Free Cash Flow $-192.70m
Cash position $343.03m
EPS (TTM) EPS $-3.74
P/E forward negative
Short interest 13.12%
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

Buy
100%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
400% 400%
-
-0.05 -0.05
400% 400%
-
- Selling and Administrative Expenses 26 26
58% 58%
-
- Research and Development Expense 176 176
98% 98%
-
-201 -201
92% 92%
-
- Depreciation and Amortization 0.05 0.05
400% 400%
-
EBIT (Operating Income) EBIT -201 -201
92% 92%
-
Net Profit -189 -189
108% 108%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
GlobeNewsWire
about 16 hours ago
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy ...
Neutral
Seeking Alpha
8 days ago
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good aftern...
Neutral
GlobeNewsWire
8 days ago
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website www.mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today